BGM
Bgm Group Ltd
NASDAQ · Pharmaceuticals
$1.14
-0.08 (-6.56%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 101.37M | 106.35M | 109.96M |
| Net Income | 12.48M | 12.42M | 13.50M |
| EPS | — | — | — |
| Profit Margin | 12.3% | 11.7% | 12.3% |
| Rev Growth | +16.4% | +7.5% | +6.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 24.16M | 23.86M | 26.94M |
| Total Equity | 113.51M | 126.32M | 122.05M |
| D/E Ratio | 0.21 | 0.19 | 0.22 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 20.71M | 22.69M | 21.79M |
| Free Cash Flow | 8.96M | 8.29M | 10.61M |